Press Releases 

Predictive Oncology Subsidiary Helomics Executes Next Phase of Agreement with Interpace to Enhance t

Three Most Recent Pittsburgh-Based Development Partnerships Demonstrate Value and Recognition for Helomics’ AI-Driven, Patient Derived “Multi-Omic” Discovery Platform MINNEAPOLIS, Minn., July 30, 2019 (GLOBE NEWSWIRE) – Predictive Oncology (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today its Helomics division has executed on an agreement between the company and Interpace Diagnostics Group, Inc. or Interpace(NASDAQ: IDXG), collectively known as ‘the Companies”, to build AI-driven models of thyroid cancer in order to enhance diagnosis of as well as therapeutic options for

Predictive Oncology Subsidiary Helomics Collaborates with UPMC to Establish a Data and Artificial In

PITTSBURGH, July 18, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) subsidiary Helomics, an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products and services, today announced a joint collaborative agreement with UPMC to study the use of artificial intelligence to improve clinical decision making for ovarian cancer patients. Helomics is a subsidiary of Predictive Oncology Inc., a company focused on applying artificial intelligence to personalized medicine and drug discovery. The collaboration will focus on using Helomics’ artificial intellig

Archive
 Follow Us
  • LinkedIn Social Icon
  • Facebook Basic Square
  • Twitter Basic Square

© 2020 Helomics Corp. All rights reserved.

  • White Twitter Icon
  • Facebook - White Circle
  • White LinkedIn Icon